Cargando…

Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease

Detalles Bibliográficos
Autores principales:	Di Pardo, Alba, Maglione, Vittorio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649462/ https://www.ncbi.nlm.nih.gov/pubmed/29089987 http://dx.doi.org/10.4103/1673-5374.215253

Ejemplares similares

Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models
por: Di Pardo, Alba, et al.
Publicado: (2016)

A Rationale for Hypoxic and Chemical Conditioning in Huntington’s Disease
por: Burtscher, Johannes, et al.
Publicado: (2021)

Tractography of the Corpus Callosum in Huntington’s Disease
por: Phillips, Owen, et al.
Publicado: (2013)

The Role of Clinical Glyco(proteo)mics in Precision Medicine
por: van der Burgt, Yuri, et al.
Publicado: (2023)

Mitochondrial Respiration Changes in R6/2 Huntington’s Disease Model Mice during Aging in a Brain Region Specific Manner
por: Burtscher, Johannes, et al.
Publicado: (2020)

Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease
por: Carrizzo, Albino, et al.
Publicado: (2014)

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Exploiting Sphingo- and Glycerophospholipid Impairment to Select Effective Drugs and Biomarkers for CMT1A
por: Visigalli, Davide, et al.
Publicado: (2020)

Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders
por: Di Pardo, Alba, et al.
Publicado: (2018)

De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Brain Region and Cell Compartment Dependent Regulation of Electron Transport System Components in Huntington’s Disease Model Mice
por: Burtscher, Johannes, et al.
Publicado: (2021)

To Sleep to Dream … No More? The Quest for Restorative Sleep in Huntington’s Disease, a Clinician’s Perspective
por: Rosas, Herminia Diana
Publicado: (2023)

Editorial: Characterization, Biosynthesis and Biological Functions of Novel Glyco-Epitopes
por: Yan, Shi, et al.
Publicado: (2022)

Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease
por: Di Pardo, Alba, et al.
Publicado: (2013)

Plant glyco-biotechnology on the way to synthetic biology
por: Loos, Andreas, et al.
Publicado: (2014)

Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington’s Disease Pre-clinical Model
por: Di Pardo, Alba, et al.
Publicado: (2019)

Factors contributing to clinical picture and progression of Huntington's disease
por: Zielonka, Daniel
Publicado: (2018)

Striving for a Realistic and Unapologetic View of Huntington’s Disease
por: Serbin, Kenneth P.
Publicado: (2022)

GlycoBioinformatics
por: Aoki-Kinoshita, Kiyoko F, et al.
Publicado: (2021)

Regulation of one-carbon metabolism may open new avenues to slow down the initiation and progression of Huntington’s disease
por: Xie, Jiahua, et al.
Publicado: (2023)

Putting the Brakes on Huntington Disease in a Mouse Experimental Model
por: Kim, Jane C., et al.
Publicado: (2015)

Histone methylation in Huntington’s disease: are bivalent promoters the critical targets?
por: Zsindely, Nóra, et al.
Publicado: (2018)

Hopping from One Cell to Another: Huntington's Disease Propagates
por: Park, Sang Myun
Publicado: (2017)

Ultra-Fast Glyco-Coating of Non-Biological Surfaces
por: Williams, Eleanor, et al.
Publicado: (2016)

Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

DNA instability in replicating Huntington's disease lymphoblasts
por: Cannella, Milena, et al.
Publicado: (2009)

Therapeutic potential of insulin-like growth factor 2 in Huntington’s disease: controlling proteostasis to alleviate the load of misfolded protein
por: Troncoso-Escudero, Paulina, et al.
Publicado: (2021)

Perspectives for Glyco-Engineering of Recombinant Biopharmaceuticals from Microalgae
por: Barolo, Lorenzo, et al.
Publicado: (2020)

Renin-angiotensin system in the central nervous system: focus on Huntington’s disease
por: de Miranda, Aline Silva, et al.
Publicado: (2023)

Plasma Metabolomics Reveal Alterations of Sphingo- and Glycerophospholipid Levels in Non-Diabetic Carriers of the Transcription Factor 7-Like 2 Polymorphism rs7903146
por: Then, Cornelia, et al.
Publicado: (2013)

New perspectives in iron chelation therapy for the treatment of Parkinson’s disease
por: Nuñez, Marco T., et al.
Publicado: (2019)

GlycoEnzOnto: a GlycoEnzyme pathway and molecular function ontology
por: Groth, Theodore, et al.
Publicado: (2022)

Can leukocyte telomere shortening be a possible biomarker to track Huntington’s disease progression?
por: Mantuano, Elide, et al.
Publicado: (2019)

Editorial: Glyco-Tools to Crack Unsolved Biomedical Needs
por: Marcelo, Filipa, et al.
Publicado: (2021)

Glyco-biomarkers: Potential Determinants of Cellular Physiology and Pathology
por: Alavi, Azita, et al.
Publicado: (2008)

Advance in the use of gold nanoparticles in the treatment of neurodegenerative diseases: new perspectives
por: Silveira, Gustavo de Bem, et al.
Publicado: (2021)

Computational Cancer Biology: An Evolutionary Perspective
por: Beerenwinkel, Niko, et al.
Publicado: (2016)

An Alternative Perspective for the Theory of Biological Control
por: Mills, Nicholas J.
Publicado: (2018)

Neurodevelopmental defects as a primer of neurodegeneration: lessons from spinal muscular atrophy and Huntington’s disease
por: Grice, Stuart J., et al.
Publicado: (2023)

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dhfm57k09gvtc7oos7qvmq24rh